NeurologyLive

09/07/2026

Could better biomarkers help clinicians determine when a patient with SMA may benefit from another therapy? 🔬

Aaron Zelikovich, MD, says the answer may ultimately require more than a single marker, combining measures such as imaging, neurofilament light, laboratory data, and clinical assessments.

Hear his perspective on dual therapy and the future of SMA care in Mind Moments 🎧
https://hubs.li/Q04wLBHb0
Spotify: https://hubs.li/Q04wLBLH0

09/07/2026

Labor Day is a time to recognize the hard work and contributions of American workers.

Today, we’re celebrating the neurologists, researchers, and health care professionals whose dedication continues to advance neurologic care and improve the lives of patients.

Wishing you a safe and happy Labor Day from NeurologyLive! 🧠

09/06/2026

🧠 A new study published in the Multiple Sclerosis Journal found that women with MS treated with disease-modifying therapies (DMTs) faced significantly higher rates of gynecologic complications, including HPV positivity, cervical dysplasia, and cervical cancer, compared with untreated women.

Researchers say the findings support adding gynecologic counseling and screening to routine MS care.

🩺 Full story: https://hubs.li/Q04wKWxR0

UCSF

09/05/2026

🧠 A Major Step Forward for Huntington Disease Treatment

🧬 uniQure has formally asked the FDA and UK regulators to approve ifezuntirgene inilparvovec, a one-time gene therapy for Huntington disease—a condition that currently has no approved treatments to slow its progression.

The therapy works by delivering a microRNA directly into the brain to help silence the gene responsible for the disease. Why this matters:
✅ 3-year data showed the treatment slowed disease progression by 75% in the highest-dose group compared to patients not receiving treatment
✅ No new safety concerns emerged over the study period
✅ About 75,000 people currently live with Huntington disease across the US, EU, and UK, with many more at risk of inheriting it

❤️ "This represents an important milestone for the Huntington disease community," said uniQure CEO Matt Kapusta. If approved, this could become the first-ever disease-modifying treatment for Huntington disease

Read more here 👉 https://hubs.li/Q04wP7qd0

uniQure submitted a BLA to FDA and an MAA to the UK's MHRA for ifezuntirgene inilparvovec, based on 3-year phase 1/2 data showing slowed Huntington disease progression.

09/05/2026

🧬 What Women With MS Should Know About a New Study

🩺 A large new study looked at more than 115,000 women with multiple sclerosis and found that those taking disease-modifying therapies (DMTs) had higher rates of certain gynecologic health issues compared to women who weren't on treatment

The study found increased rates of:
✅ HPV infection
✅ Cervical cell changes (dysplasia)
✅ Cervical cancer
✅ Other infections and gynecologic conditions

📋 Lead researcher Riley Bove, MD (UCSF) recommends women starting these treatments make sure they're up to date on HPV vaccination, stay alert to any new symptoms, and keep up with recommended cervical cancer screenings

Researchers believe DMTs may make it harder for the body to clear HPV infections on its own, which over time could raise these risks Importantly, researchers note the overall risk remains low, and more research is needed to confirm how DMTs affect this risk over time

Read more here 👉 https://hubs.li/Q04wxB850

A recently published multiple sclerosis study suggests disease-modifying therapy use may be associated with higher rates of human papillomavirus positivity, cervical abnormalities, and other gynecologic complications.

09/05/2026

🇪🇺 New Parkinson's Treatment Approved in Europe

💊 The European Commission has approved Hopledo, a modified-release version of carbidopa/levodopa, for adults with Parkinson disease whose motor fluctuations aren't well controlled by standard treatment

This formulation is already available in the US as Crexont—and clinical trial data shows it can help patients:
✅ Get more hours of good symptom control each day (called "Good ON time")
✅ Take fewer daily doses (about 3 vs. 5 with standard treatment)
✅ Experience similar safety compared to standard levodopa

🧠 "This is an important advancement in levodopa therapy," said Günter Höglinger, MD, of LMU University Hospital Munich.

Read more here 👉 https://hubs.li/Q04wxg9Y0

The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.

09/04/2026

🧠📓 Newly published data: 91.3% of U.S. counties have zero UCNS-certified headache specialists, and the gaps are widest in areas with greater socioeconomic deprivation.

Lead author Bradley Ong, MD, of Cleveland Clinic, breaks down what this means for patients with migraine and other headache disorders who lack local subspecialty access.

📊 Read the full analysis and Dr. Ong's take on where the workforce gaps come from 👇

https://hubs.li/Q04wDfSd0

09/04/2026

Think you know the facts? Think again.

A new NeurologyLive series is coming soon — and it’s here to question some of the most widely held beliefs in neurology.

Gray Areas launches September 7, featuring conversations with leading clinicians and researchers who will unpack common myths, challenge misconceptions, and explore what the evidence really says.

🎙️ Short. Focused. Evidence-driven.
🧠 New episodes every two weeks.

Stay tuned.

09/04/2026

IT’S ALMOST TIME! 🚨

The Carolina Neuromuscular Disease Summit is just around the corner — and this is your last chance to register!

Join experts and colleagues for important conversations, the latest insights, and opportunities to connect with the neuromuscular disease community.

📅 September 19–20
📍 Charlotte, NC

Don’t miss out. Register now: https://hubs.li/Q04wCnw50

09/03/2026

❤️ A Step Forward for Heart Attack Patients with High-Risk Blood Clots

🆕 research presented at the European Society of Cardiology Congress 2026 shows a promising option for STEMI (heart attack) patients with a particularly challenging complication: large blood clots that are hard to fully clear during standard treatment
🫀 The NATURE trial found that adding a specialized clot-retrieval device (enVast) to standard heart attack treatment:
✅ Reduced heart muscle damage by about 26% compared to standard care alone
✅ Resulted in zero strokes or deaths at 30 days in the treatment group
✅ Showed a strong safety profile overall

🩺 "This represents important new evidence for mechanical thrombectomy in patients with large thrombus burden," said lead researcher Marco Valgimigli, MD, PhD

This approach differs from earlier "clot suction" methods that didn't show consistent benefit—NATURE specifically targeted patients most likely to benefit from this more advanced retrieval technique

Read more here 👉 https://hubs.li/Q04wh61h0

The randomized NATURE trial, presented as late-breaking science at ESC Congress 2026, showed that enVast-assisted thrombectomy reduced infarct size versus standard PCI in STEMI with large thrombus burden.